Results 241 to 250 of about 9,686,810 (338)

an empirical study of the effect of leadership influence on decision outcomes in different sized jury panels [PDF]

, 1975
Beth A. Eakin
openalex   +1 more source

ADVERSE NEURODEVELOPMENTAL OUTCOME OF MODERATE NEONATAL HYPOGLYCEMIA [PDF]

, 1988
COLE, TJ, LUCAS, A, MORLEY, R
core  

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

Molecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche, Renske Imschoot, Béatrice Lintermans, Lode Denolf, Joachim Taminau, Charlotte Fieuws, Geert Berx, Kris Gevaert, Kathleen B. M. Claes   +8 more
wiley   +1 more source

Physiological Signal Entropy in Pediatric Traumatic Brain Injury: Looking Beyond the Obvious: A STARSHIP Study. [PDF]

Crit Care Explor
Bögli SY, Smith CA, Hutchinson P, Agrawal S, Smielewski P, Studying Trends of Autoregulation in Severe Head Injury in Paediatrics (STARSHIP) study team.   +5 more
europepmc   +1 more source

Outcome of Judicial Review Jobcentre Plus referrals [PDF]

, 2012

core  

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

Standardizing patient-reported outcomes across diseases: development of a novel generic patient-reported outcome set. [PDF]

Front Health Serv
Long P, Rogge A, Porth AK, Gross E, Fierens L, de Rooij BH, Kamminga N, Stamm T.   +7 more
europepmc   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Validation of Telehealth Outcome Categories for Patient Safety: Systematic Literature Review.

JMIR Med Inform
Palojoki S, Lehtonen L, Vuokko R.
europepmc   +1 more source

Neural mechanisms underlying reward processing and social cognition: A replication study with a Japanese sample. [PDF]

PLoS One
Ohnishi K, Sugawara M, Mano Y, Suzuki S.
europepmc   +1 more source